Nevertheless, these potential effects require further research validation, and no definitive clinical application protocols have been established to date
The Evidence on Cancer Risk The most common concern regarding tirzepatide and the thyroid stems from "black box warnings" found in prescribing information
The semaglutide-niacinamide compound has not been reviewed, approved, or evaluated by the FDA for safety or efficacy
GLP-1RAs inhibit RGC apoptosis in glaucoma through GABAergic signaling, but their role in AMD, characterized by oxidative stress and choroidal neovascularization, needs further investigation ( The latest diabetic retinopathy preferred practice guidelines from the American Academy of Ophthalmology indicate that the rising use of GLP-1RAs may lead to quick glycemic control and severe hypoglycemia and has been reported to cause higher rates of retinopathy complications, especially in patients with early-stage DR ( 4.2 Delivery optimization Systemic administration of GLP-1RAs reduces their availability in the retina and can lead to off-target effects, particularly gastrointestinal issues
The outlook for the market remains positive, supported by rising health awareness, expanding reimbursement frameworks, and sustained technological advancement
Cagrilintide acts on calcitonin-related receptors with some glucagon-adjacent effects